INAB vs. CRTX, TARA, ENLV, INKT, SRZN, NKGN, ACHL, PLUR, ESLA, and BCLI
Should you be buying IN8bio stock or one of its competitors? The main competitors of IN8bio include Cortexyme (CRTX), Protara Therapeutics (TARA), Enlivex Therapeutics (ENLV), MiNK Therapeutics (INKT), Surrozen (SRZN), NKGen Biotech (NKGN), Achilles Therapeutics (ACHL), Pluri (PLUR), Estrella Immunopharma (ESLA), and Brainstorm Cell Therapeutics (BCLI). These companies are all part of the "medical" sector.
Cortexyme (NASDAQ:CRTX) and IN8bio (NASDAQ:INAB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership, analyst recommendations and community ranking.
Cortexyme has a beta of 1.4, suggesting that its stock price is 40% more volatile than the S&P 500. Comparatively, IN8bio has a beta of 0.05, suggesting that its stock price is 95% less volatile than the S&P 500.
63.2% of Cortexyme shares are held by institutional investors. Comparatively, 92.1% of IN8bio shares are held by institutional investors. 27.9% of Cortexyme shares are held by insiders. Comparatively, 33.0% of IN8bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Cortexyme received 135 more outperform votes than IN8bio when rated by MarketBeat users. However, 67.86% of users gave IN8bio an outperform vote while only 64.44% of users gave Cortexyme an outperform vote.
IN8bio is trading at a lower price-to-earnings ratio than Cortexyme, indicating that it is currently the more affordable of the two stocks.
IN8bio has a consensus price target of $10.75, suggesting a potential upside of 964.36%. Given Cortexyme's higher probable upside, analysts plainly believe IN8bio is more favorable than Cortexyme.
IN8bio's return on equity of -70.96% beat Cortexyme's return on equity.
In the previous week, IN8bio's average media sentiment score of 0.00 equaled Cortexyme'saverage media sentiment score.
Summary
IN8bio beats Cortexyme on 7 of the 12 factors compared between the two stocks.
Get IN8bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for INAB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
